Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > TH1902 ClinicalTrials.gov Update

<< Previous

Bullboard Posts

Next >>

Comment by Garp1on Jan 30, 2023 4:22pm

123 Views

Post# 35254833

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TH1902 ClinicalTrials.gov Update

I maintain my position. A hostile takeover bid even if low ball, is the best cenario. This would force Thera to disclose the current state of their business. If they can't convince the shareholders that it's not in their best interest or that other suiters exist, then we standby. Otherwise we stop this joke of a business, take the offer and move on to other things.

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price